Answers are grounded in this paper and cite their sources.
Background: Bevacizumab is an extensively used biological anticancer medicine, while the introduction of biosimilars has created opportunities to increase competition, improve access, and reduce treatment costs. We aimed to evaluate long-term trends in bevacizumab utilization and expenditure in Croatia, with particular emphasis on the impact of biosimilar market entry. Methods: National bevacizumab utilization and pharmaceutical expenditure data for 2006 to 2025 were obtained from the IQVIA database. Utilization was assessed according to total consumption, vial size, brand, and market share, while average expenditure per vial was calculated. Trends before and after biosimilar introduction were evaluated. Results: Total bevacizumab consumption increased substantially, from 127 400 mg in 2006 to 10 044 600 mg in 2025. Following biosimilar introduction in 2020, utilization rapidly shifted from Avastin ® to biosimilar products, with biosimilars accounting for more than 94% of utilization by 2025. During the same period, average vial prices decreased substantially. Conclusion: Biosimilar market entry was associated with rapid market transformation, increased competition, and lower unit costs while overall bevacizumab utilization continued to increase.
No takes yet. Share an insight, caveat, or question.
Belančić et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: